- Home
- ALXO vs RANI Comparison
ALXO vs RANI Comparison
Compare ALXO & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- RANI
- Stock Information
- Founded
- ALXO 2015
- RANI 2012
- Country
- ALXO United States
- RANI United States
- Employees
- ALXO N/A
- RANI N/A
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- RANI Medicinal Chemicals and Botanical Products
- Sector
- ALXO Health Care
- RANI Health Care
- Exchange
- ALXO Nasdaq
- RANI Nasdaq
- Market Cap
- ALXO 24.0M
- RANI 23.2M
- IPO Year
- ALXO 2020
- RANI 2021
- Fundamental
- Price
- ALXO $0.60
- RANI $0.51
- Analyst Decision
- ALXO Strong Buy
- RANI Strong Buy
- Analyst Count
- ALXO 6
- RANI 4
- Target Price
- ALXO $3.30
- RANI $7.75
- AVG Volume (30 Days)
- ALXO 494.7K
- RANI 4.6M
- Earning Date
- ALXO 08-07-2025
- RANI 08-05-2025
- Dividend Yield
- ALXO N/A
- RANI N/A
- EPS Growth
- ALXO N/A
- RANI N/A
- EPS
- ALXO N/A
- RANI N/A
- Revenue
- ALXO N/A
- RANI $1,200,000.00
- Revenue This Year
- ALXO N/A
- RANI N/A
- Revenue Next Year
- ALXO N/A
- RANI N/A
- P/E Ratio
- ALXO N/A
- RANI N/A
- Revenue Growth
- ALXO N/A
- RANI N/A
- 52 Week Low
- ALXO $0.40
- RANI $0.39
- 52 Week High
- ALXO $6.08
- RANI $3.75
- Technical
- Relative Strength Index (RSI)
- ALXO 63.55
- RANI 51.28
- Support Level
- ALXO $0.44
- RANI $0.40
- Resistance Level
- ALXO $0.64
- RANI $0.59
- Average True Range (ATR)
- ALXO 0.04
- RANI 0.06
- MACD
- ALXO 0.02
- RANI 0.01
- Stochastic Oscillator
- ALXO 76.35
- RANI 31.88
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About RANI Rani Therapeutics Holdings Inc.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.